HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Reduced intensity allogeneic hematopoietic cell transplantation can induce durable remission in heavily pretreated relapsed Hodgkin lymphoma.

Abstract
Hodgkin lymphoma (HL) can be aggressive and intractable in some cases. Patients who relapse after autologous HCT (auto-HCT) have limited treatment options. City of Hope reports our experience in the use of reduced intensity allogeneic hematopoietic cell transplantation (allo-HCT) in 24 heavily pretreated patients with relapsed HL, between January 2003 and December 2008. The median number of prior therapies was 5; 20/24 patients had prior auto-HCT. The conditioning regimen for all patients was fludarabine and melphalan. With a median follow-up for living patients of 39.0 months, at 2 years the overall survival (OS) was 60% (95% CI 42, 72) and the progression-free survival was 27% (95% CI 22, 32). Non-relapse mortality was 13.1% (95% CI 5.1, 31.4) at 2 years. The incidence of grade II-IV aGVHD was 45.8% and 8.3% for grade III-IV. Allo-HCT in heavily pretreated relapsed Hodgkin lymphoma is feasible, tolerable, and can induce durable clinical remissions.
AuthorsRobert Chen, Joycelynne M Palmer, Leslie Popplewell, Jessica Shen, Eileen Smith, Maria Delioukina, Neil Kogut, Joseph Rosenthal, Stephen Forman, Auayporn Nademanee
JournalAnnals of hematology (Ann Hematol) Vol. 90 Issue 7 Pg. 803-8 (Jul 2011) ISSN: 1432-0584 [Electronic] Germany
PMID21210120 (Publication Type: Journal Article)
Chemical References
  • Antineoplastic Agents
  • Myeloablative Agonists
  • Vidarabine
  • fludarabine
  • Melphalan
Topics
  • Adolescent
  • Adult
  • Antineoplastic Agents (therapeutic use)
  • Clinical Trials as Topic
  • Disease Progression
  • Disease-Free Survival
  • Female
  • Graft vs Host Disease (prevention & control)
  • Hematopoietic Stem Cell Transplantation (methods)
  • Hodgkin Disease (drug therapy, prevention & control, surgery)
  • Humans
  • Male
  • Melphalan (therapeutic use)
  • Middle Aged
  • Myeloablative Agonists (therapeutic use)
  • Recurrence
  • Transplantation Conditioning
  • Transplantation, Homologous (methods)
  • Treatment Outcome
  • Vidarabine (analogs & derivatives, therapeutic use)
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: